The Indian Pharmaceutical Industry: New Strategies in a Changing World

Date: June 22, 2010
Pages: 268
Price:
US$ 1,740.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IA44FB008B3EN
Leaflet:

Download PDF Leaflet

The Indian Pharmaceutical Industry: New Strategies in a Changing World
The days when the Indian pharmaceutical industry was synonymous with cheap generic drug production are passing. While generics continue to play a major part in the industry’s success, many companies have started down the long road of drug discovery, novel product development and pharma services.

With high-quality research, low-cost manufacturing facilities and educated personnel, the Indian pharmaceutical industry presents both a competitive threat and partnering opportunities.

A significant international industry

India is the world’s fourth largest producer of pharmaceuticals by volume, accounting for around 8% of global production. In value terms, production accounts for around 1.5% of the world total. The Indian pharmaceutical industry directly employs around 500,000 people and is highly fragmented. While there are around 270 large R&D based pharmaceutical companies in India, including multinationals, government-owned and private companies, there are also around 5,600 smaller licensed generics manufacturers, although in reality only around 3,000 companies are involved in pharmaceutical production. Most small firms do not have their own production facilities, but operate using the spare capacity of other drug manufacturers.

A new approach

The advent of pharmaceutical product patent recognition in January 2005 changed the ground rules for Indian companies. In the run up to the new post-patent era and since, the Indian industry has been evolving. R&D departments are moving away from reverse-engineering in favour of developing novel drug delivery systems and discovery research. It is anticipated that the experience of selling generics in the international market will hold Indian companies in good stead for selling their own branded products to these markets in the future.

Focus on...current and future markets

The dynamics of the domestic Indian market have always encouraged Indian industry to pursue overseas lines of business. Expansion comes at a cost and some companies have had to restructure. In June 2009, Wockhardt divested its German business, esparma and more recently, in March 2010, Orchid sold its generic injectable formulations business to Hospira but came out of the deal with a long term supply agreement for its APIs.

INDIA

India remains an important market for the vast majority of Indian companies. The indigenous industry supplies around 70% of the country’s pharmaceuticals. The proportion of revenue derived from India depends largely on the strategy of the individual company and its penetration into overseas markets. For example, while Zydus Cadila aims to grow rapidly overseas, India remains its most important market, accounting for 55.8% of revenue in fiscal 2008/09. India is also Cipla’s key market, generating almost half of the company’s revenue in 2008/09, although this percentage has been declining in recent years as the company has increasingly targeted overseas markets. Other companies, such as Dr. Reddy’s, are less reliant on the Indian market; in 2008/09, India contributed just 17% of the company’s global revenue.

INTERNATIONAL DEVELOPMENT

The attractive opportunities offered by the loss of patent protection on several major products in the coming period, and resolution of the biosimilar regulatory issue in the US, has to be offset against price reduction pressures driven by the ongoing economic downturn and aggressive competition for the business that is on offer.

USA: The largest generic market and the most sought after target for Indian companies involved in the generic business, is the US. As more companies gained the expertise to file for FDA approval, the number of ANDAs approved increased dramatically. In 2005, the number increased to 52 and subsequently increased year-on-year, to reach 132 in 2008. In 2009, the total number of ANDA approvals was 125. In the first quarter of 2010, a further 20 were approved.

UK: Over 80% of prescriptions in the mature UK market are written generically. The UK has always been a focus for Indian companies with 9 companies running 11 manufacturing sites. Between January 2009 and January 2010, Indian companies had more than 260 marketing authorisations approved by the UK’s Medicines and Healthcare Regulatory Agency (MHRA) for a wide range of products. During this period, Ranbaxy received 55 approvals; Dr. Reddy’s received 54; Aurobindo received 39; and, Lupin received 25.

Europe: Beyond the UK and Germany, significant European markets have been slow to adopt a vigorous generics drugs policy. However, pressure on governments to cut costs in the face of burgeoning drugs bills and economic recession, are seeing countries such as France, Italy and Spain exploring the increased use of generics. A number of Indian companies are either monitoring them from the sidelines or have already identified growth potential; Ranbaxy, for example is established in France, Germany, Italy and Spain.

Brazil: Brazil is perhaps the most notable emerging generic market in recent years. According to the Brazilian generic industry association, Pró-Genéricos, prices of generic medicines have to be at least 35% cheaper than prices of original medicines but, in practice, they are up to 50% cheaper. In 2009, generic medicines represented 19.4% of the pharmacy sector by volume, increasing 19.0% over the previous year to 330.0 million units. In value terms, pharmacy sales of generic medicines increased by 24.0% to R$4.5 billion (US$2.2 billion). Indian companies have been present in the Brazilian market for several years. In 2008, Indian pharmaceutical exports to Brazil were valued at around US$166 million per year and made up a significant part of all trade between India and Latin America.

Australia: Due to low prices of branded products, Australia is not yet a major market for generics. A number of leading drugs are due to lose patent protection, but price competition tends to be muted for off-patent drugs. The government is, however, currently looking at ways to boost generic consumption in an effort to rein in the overall drugs bill. The market is beginning to attract Indian companies, a number of which have gained approval from the Therapeutic Goods Administration for their manufacturing facilities and a range of products.

Indian pharmaceutical companies are no strangers to competition. The Indian market is highly competitive with more than 300 organised players and branded promotional costs associated with every product, yet the industry is able to offer low-priced products and remain profitable in India. However, whether the Indian industry will be able to maintain the pace of expansion across the world is questionable in the current economic climate.

The Indian Pharma Industry - looking beyond generics

The Indian pharmaceutical industry has a long history of reverse-engineering and its ability to produce and distribute globally generic copies of pharmaceutical products is well proven. Post TRIPs, the R&D focus of Indian companies has shifted towards novel drug delivery systems or discovery research. But the global launch of innovative new products is still some way off, so what are the options for companies going forward?

In-licensing and custom manufacturing are alternative strategies to generics

Building upon its strengths in chemical synthesis and process engineering, the availability of highly-skilled labour and a low-cost manufacturing base, some companies have elected to pursue alternative business strategies.

Piramal Healthcare has always partnered global innovator companies and, in addition to an extensive Indian generic business, is a global player in custom manufacturing and has a number of early stage development candidates. In May 2010, it was announced that Abbott had agreed to pay a total of US$3.7 billion for the domestic drug business, leaving Piramal to concentrate on its research, formulation and customer manufacturing businesses.

Another company with a diverse portfolio of services is Jubilant Organosys. The company’s main focus is its Pharmaceuticals and Life Sciences Products and Services business, which has grown significantly over the last few years. Jubilant is active in APIs, proprietary products, contract manufacturing of liquid and lyophilized sterile injectables, ointments, creams and liquids, radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare.

Biosimilars

The resolution of the regulatory issues surrounding biosimilars in the USA has removed at least one obstacle to the development of these products. As one of the leading producers of generic drugs, it is logical that Indian companies would see biosimilars as a natural follow-on business. Recent milestones in the development of biosimilars include:
  • Biocon signed a collaborative agreement with Mylan in June 2009 on the development, manufacturing, supply and commercialisation of multiple, high-value generic biologic compounds for the global marketplace. The collaboration combines Biocon’s scientific and biologics manufacturing with Mylan's global commercial footprint.
  • In March 2010, Ranbaxy and the San Diego, California-based Pfenex announced that they had entered into an agreement under which Ranbaxy will develop an undisclosed biosimilar therapeutic produced in the Pfenex Expression Technology platform, a pseudomonas-based recombinant protein technology.
  • In February 2009, Wockhardt announced that it had launched Glaritus, a recombinant long-acting human insulin analogue, in India. The company commented that it was the first company in the world, after the innovator, to launch this particular type of insulin, which works slowly for over 24 hours.
FOREWORD

THE INDIAN PHARMACEUTICAL INDUSTRY


Introduction
  Indian bases
  Sales revenue
The advent of the product patent regime in India
  Background
    The Patents (Amendments) Bill, 2005
    Mashelkar Committee Report, December 2006
  What effect has the product patent regime had on the pharmaceutical industry?
    Looking beyond reverse-engineering
    In-licensing and custom manufacturing
Key markets now and in the future
  Established and emerging generic markets
    The United States
    Authorised generics – threat or opportunity?
    Europe
    South Africa
    Brazil
    Australia
  Biosimilars
    Biosimilars and Indian Companies
  India’s competitive advantage
  Foreign acquisitions
  Exports

COMPANY PROFILES

ALEMBIC
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Dabur Pharma Acquisition
  Products
    Domestic Formulations
    APIs
    International Formulations
    Generics
  Financials
AUROBINDO PHARMA
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Trident Life Sciences acquisition
    Licensing and supply agreements with Pfizer
    TAD Italy acquisition
    Pharmacin acquisition
    Acquisition of US facility
    Milpharm: Aurobindo’s first acquisition in Europe
  Products
    APIs
    Domestic Formulations
    International Generics
      US and Canada
      CNS
      Antibacterials
      Antiretrovirals
      Cardiovascular
      European Union
      South Africa
      Australia
  Financials
BIOCON
  Company Strategy
    Manufacturing
    R&D
  Major Developments
    Acquisitions
      Biocon buys majority stake in German marketing company
      Acquisition of asset of Nobex Corporation
    Agreements
      Biocon to acquire CIMAB’s stake in BBPL
      Syngene collaborates with Endo
      Amylin and Biocon to develop/commercialise novel phybrid for diabetes
      Mylan/Biocon form collaboration for generic biologics
      Abraxis and Biocon announce G-CSF partnership
      Invitrogen/Biocon sign agreement to market insulin to cell culture market
      Biocon/Vaccinex partner to discover and develop therapeutic Abs
    Products
      APIs
      Domestic Formulations
      International Formulations
      Insugen
    Financials
CIPLA
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Strategic Alliances & Agreements
      Akorn
      Malaria agreement with DNDi
    Divestiture of Cipla Medpro
  Products
    APIs
    Domestic Formulations
    International Generics
      US
    Europe
  Financials
CLARIS LIFESCIENCES
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Marketing agreement with Pfizer
  Products
    Domestic Formulations
    International Generics
DR. REDDY’S
  Company Strategy
    Manufacturing
    USP’s Pharmaceutical Ingredient Verification Programme
    R&D
      Perlecan
      Cancer
      Diabetes
    Key Markets
  Major Developments
    Mergers & Acquisitions
      BASF contract manufacturing operations
      Dowpharma’s UK Small Molecules business
      Jet Generici
      betapharm
      Roche’s Mexico API facility
    Joint Ventures
      China - Kunshan Rotam Reddy Pharmaceutical Co., Ltd.
      South Africa - Dr. Reddy’s Laboratories (Proprietary) Ltd.
  Agreements
    Dr Reddy's enters strategic alliance with Aegis Therapeutics
    Dr. Reddy’s files fondaparinux ANDA under Alchemia agreement
    Dr Reddy’s makes dermatology product advances
    TMH/Dr Reddy's sign agreement to create self-injectable product
    Aquapharm signs new agreement and extends R&D licence with Dr Reddy's
    7TM/Dr. Reddy’s enter drug-discovery collaboration
    Dr. Reddy’s and Torrent sign Russian lisinopril agreement
    Dr. Reddy's and ClinTec Co-Development Agreement
    Dr. Reddy’s and Argenta announce R&D collaboration
    Dr. Reddy’s and Rheoscience R&D collaboration
    Dr. Reddy's/Pharmascience sign multi-product agreement
  Litigation
    Clarinex-D settlement with Schering-Plough and Sepracor
    AstraZeneca sues Dr Reddy’s over generic zafirlukast
    US court affirms that Eisai's Aciphex patent is valid and enforceable
  Products
    APIs
    Domestic Formulations
    International Generics
      US
      Europe
  Financials
GLENMARK
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Mergers & Acquisitions
    Glenmark begins Polish venture
    Glenmark purchases rights to CHR-1103 and CHR-1201 from Chromos
    Medicamenta, Czech Republic
    Bouwer Bartlett, South Africa
  Agreements
    Lilly/Glenmark form TRPV1 partnership
    R&D agreement with Dyax for therapeutic antibodies
    Merck KGaA
    Royalty deal with Paul Capital Partners
    Lehigh Valley Technologies
    Aspen USA
    Generics agreement with InvaGen for US market
  Litigation
    Glenmark launches fluticasone patent challenge; Nycomed files lawsuit
    Abbott’s trandolapril/verapamil product
  Products
    APIs
    Domestic Formulations
    International Generics
      US
      Europe
      Brazil
  Financials
JUBILANT ORGANOSYS
  Company Strategy
    Manufacturing
    R&D
    Acquisitions
      Draxis Health
      Speciality Molecules Pvt. Ltd.
      Hollister-Stier Laboratories
      Trinity Laboratories/Trigen Laboratories
    Joint Ventures
      Jubilant/UAB/SRI form drug-discovery JV
      Collaboration and JV with Eli Lilly
  Agreements
    Jubilant and Endo expand oncology drug discovery partnership
    Duke and Jubilant announce intent for global research/drug-development partnership
    Jubilant to provide preclinical drug candidates for AstraZeneca's pipeline
    Distribution agreement with Guerbet
    Jubilant and BioLeap enter drug-discovery alliance
    Jubilant in Drug Discovery partnership with Amgen
    Neoprobe signs non-binding LoI with Draximage for Lymphoseek distribution
  Products
    APIs
    International Generics
      US
      Canada
      Europe
  Financials
LUPIN
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Acquisitions
      Multicare Pharmaceuticals Philippines
      Pharma Dynamics
      Generic Health
      Hormosan Pharma GmbH
      Kyowa Pharmaceutical Industry
      Rubamin Laboratories
    Agreements
      Lupin/Salix to develop ER rifaximin using bioadhesive technology
      Lupin/Forest agree US marketing pact for AeroChamber Plus
      GSK Philippines
    Litigation
      Depomed files lawsuit against Lupin
      Warner Chilcott files oral contraceptive litigation against Lupin
      Lupin settles venlafaxine litigation with Wyeth
      Lupin/Schering-Plough settle desloratadine litigation
    Products
      APIs
      Domestic Formulations
      International Formulations
        US
        Europe
    Financials
MATRIX LABORATORIES
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Mergers, Acquisitions & Divestitures
    Aspen and Matrix end joint venture
    Acquisition of residual holding in MChem
    Mylan acquires Matrix
    Matrix gains 43% stake in Explora
    Matrix acquires Docpharma
    Matrix purchases finished dosage facility
  Agreements
    Clinton HIV/AIDS Initiative
  Litigation
    Mylan/Matrix enter settlement deal with Pfizer for Vfend Tablets
    Daiichi Sankyo sues Matrix for Azor patent infringement
  Products
    APIs
    International Generics
  Financials
ORCHID CHEMICALS & PHARMACEUTICALS
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Sale of generic injectable formulations business to Hospira
  Agreements
      Ranbaxy
      Actavis
      Alpharma (now Actavis)
    Acquisitions & Joint Ventures
    Bexel Pharmaceuticals Inc.
    Biotechnological Chemical Development Ltd.
    NCPC Orchid Pharmaceuticals Ltd.
  Litigation
  Products
    APIs
    Domestic Formulations
    International Generics
      US
      Europe
  Financials
PIRAMAL HEALTHCARE
  Company Strategy
    Abbott to acquire Piramal's Healthcare Solutions Business
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Mergers & Acquisitions
    Bharat Serums and Vaccines’ anaesthetic products business
    Minrad International
    RxElite’s inhalation anaesthetic gas distribution business
    Haemaccel Brands Group of PlasmaSelect AG, Germany
    Pharmaceuticals business of Healthline Private Limited, Bangalore
    Boots Piramal Healthcare
    Pfizer’s Morpeth facility
  Agreements & Joint Ventures
    Eli Lilly
    Napo Pharmaceuticals
    BioSyntech
    AstraZeneca
  Products
    APIs
    Domestic Formulations
    International Formulations
  Financials
RANBAXY
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Daiichi Sankyo to commercialise products in Mexico through Ranbaxy subsidiary
    Daiichi Sankyo acquires Ranbaxy
      Industry comment
    FDA takes regulatory action against Ranbaxy
    Congressional Committee expands Ranbaxy probe to include PEPFAR programme
    Mergers & Acquisitions
      Ranbaxy acquires product rights and facility from Biovel
      Ranbaxy acquires dermatology brands from Bristol-Myers Squibb
      Ranbaxy acquires Be-Tabs for US$71 million
      Ranbaxy acquires GSK's Mundogen generic business in Spain
      Ranbaxy acquires Terapia
      Ranbaxy acquires generic product portfolio from Efarmes
    Divestitures
      Ranbaxy (Guangzhou China) Limited (RGCL)
  Agreements
    Ranbaxy to market Gliadel for gliomas in India
    Cipher/Ranbaxy enter agreement for CIP-Isoptretinoin acne treatment
    Ranbaxy/Merck enter anti-infective drug-discovery and -development collaboration
    Ranbaxy and Orchid enter long-term strategic alliance
    Ranbaxy/DBT collaborate to develop TB therapeutics
    Ranbaxy signs first biosimilars agreement
    R&D Agreement with GlaxoSmithKline
    Ipca and Ranbaxy sign deal for US market
    Ranbaxy signs Canadian licensing and supply agreements with Janssen-Ortho
    Ranbaxy to market Lupin’s TB brands in Africa
  Litigation
    Ranbaxy and Takeda settle Actos litigation
    Pfizer and Ranbaxy settle majority of worldwide atorvastatin litigations
    AstraZeneca settles esomeprazole patent litigation with Ranbaxy; enters further agreements
    Forest and Merz file second suit against memantine challengers
    Ranbaxy settles possible litigation with GSK over sumatriptan
    Ranbaxy, Astellas and Boehringer resolve tamsulosin US patent litigation
    Novartis sues Ranbaxy over valsartan
    Ranbaxy and Goldshield win SFO cases
    UK Department of Health legal action settled
  Products
    APIs
    Domestic Formulations
    International Formulations
      Ranbaxy/Daiichi Sankyo global partnership
      US
      Canada
      Europe
      Australia
      Japan
      Brazil
  Financials
STRIDES ARCOLAB
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Acquisitions, Agreements & Joint Ventures
    Strides to acquire injectable facility in Brazil from Aspen
    Strides & Aspen restructure oncology partnership
    Pfizer and Strides collaborate on generics
    Ascent Pharmahealth
    GlaxoSmithKline
    Sagent
    Grandix
    Joint venture relationship for Spain and Portugal
    Akorn-Strides
  Products
    Domestic Formulations
    International Generics
      US
  Financials
SUN PHARMA
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Mergers & Acquisitions
    Taro Pharmaceutical Industries
    Chattem Chemicals
    Able Laboratories
    Valeant
  Litigation
    Orion sues Sun Pharma to enforce patent covering Comtan
  Products
    APIs
    Domestic Formulations
    International Generics
      US
      Europe
  Financials
TORRENT PHARMACEUTICALS
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Mergers & Acquisitions
    Heumann Pharma Generics
  Agreements
    Torrent signs licence and supply agreement with AstraZeneca
    Dr Reddy’s and Torrent sign Russian lisinopril agreement
    Torrent Pharma licenses AGE compound to Novartis
  Products
    Domestic Formulations
    International Generics
      US
      Brazil
      Financials
WOCKHARDT
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Divestitures
    Wockhardt sells its German business
    Acquisitions
    Morton Grove
    Negma Laboratories
    Pinewood Laboratories
  Agreements & Joint Ventures
    Wockhardt and Sinclair Pharma reach in-licensing and collaborative agreements
    IDC and Wockhardt co-develop insulin pens for Indian market
    Li-Taka Pharmaceuticals
    Wockhardt Mexico
    Wockhardt South Africa
  Litigation
    Orion and Wockhardt settle entacapone-based products litigation
  Products
    APIs
    Domestic Formulations
    International Generics
      US
      Europe
  Financials
ZYDUS CADILA
  Company Strategy
    Manufacturing
    R&D
    Key Markets
  Major Developments
    Mergers & Acquisitions
      Simayla Pharmaceuticals
      Etna Biotech
      Laboratorios Combix
      Quimica e Farmaceutica Nikkho do Brasil
      Nippon Universal Pharmaceutical
      Liva Healthcare
  Agreements & Joint Ventures
    Zydus and Lilly collaborate on CV drug discovery/development
    Zydus collaborates with WHO to develop MAb cocktail for rabies
    Nycomed chemical production moved to Zydus Nycomed
    Karo Bio/Zydus Cadila sign research agreement for novel GR modulators
    Evolupharn and Aerocid
    Bharat Serums and Vaccines
    Venus Remedies
    Mallinckrodt
  Litigation
    Three Rivers sues Zydus Cadila for ribavirin patent infringement
  Products
    APIs
    Domestic Formulations
    International Generics
      US
      Europe
      Japan
      Brazil
  Financials

SOURCES

Espicom Sources
Others

LIST OF TABLES

Indian Company Sales, 2009
FDA ANDA Approvals, 2002-2010 (Number)
Indian Pharmaceutical Companies’ US Subsidiaries
FDA ANDA Approvals, January 2008 – March 2010
Indian Pharmaceutical Companies’ EU Subsidiaries
UK Marketing Authorisations, 2008-2010
Indian Company Registrations of Generic Medicines in Brazil, November 2009
Indian Companies’ Foreign Acquisitions
Export Summary, 2004-2008 (US$000)
Retail Medicament Exports, 1998-2008 (US$000)
Alembic’s Manufacturing Facilities
Alembic: Top 8 Brands
Alembic: FDA ANDA Approvals, 2009
Alembic: Financial Results 2006-2010
Aurobindo Pharma: Manufacturing Facilities
Aurobindo Pharma: Key Subsidiaries
Aurobindo Pharma: ANDA Approvals, 2004-2010
Cephazone Pharma: FDA ANDA Approval, 2007
Aurobindo UK MHRA Authorisations, 2006-2009
Milpharm UK MHRA Authorisations, 2006-2009
Aurobindo Pharma: Financial Results, 2005-2009
Biocon: Financial Results, 2006-2010
Cipla: Manufacturing Facilities
Cipla: FDA ANDA Approvals
Cipla: Tentative FDA ANDA Approvals
Cipla: Tentative FDA NDA Approvals
Cipla: Financial Results, 2006-2010
Claris Lifesciences: Key Subsidiaries
Claris Lifesciences: FDA ANDA Approvals, 2008
Dr. Reddy’s: Manufacturing Facilities
Dr. Reddy’s: Regional Headquarters and Key Subsidiaries
Dr. Reddy’s: Top 10 Brands in India, 2005-2009
Dr. Reddy’s: FDA ANDA Approvals, 2002-2010
Dr. Reddy’s: UK MHRA Marketing Authorisations, 2006-2010
Dr. Reddy’s: Financial Summary, 2006-2010
Glenmark Pharmaceuticals: Manufacturing Facilities
Glenmark Generics: Manufacturing Facilities
Glenmark: Key Subsidiaries
Glenmark: FDA ANDA Approvals, 2006-2010
Glenmark: UK MHRA Authorisations, 2008-2009
Glenmark: ANVISA Registered Generics, 2009
Glenmark: Financial Results, 2006-2010
Jubilant Organosys: Manufacturing Facilities
Cadista (Jubilant): FDA ANDA Approvals, 2004-2010
Pharmaceutical Services Incorporated (PSI): MHRA Authorisations, 2007
Jubilant Pharmaceuticals NV: MHRA Authorisations, 2009-2010
Jubilant Organosys: Financial Results, 2006-2010
Lupin: Manufacturing Facilities
Lupin: Leading Brands in India, 2008
Lupin: FDA ANDA Approvals, 2003-2010
Lupin: Tentative FDA Approvals
Lupin: UK MHRA Authorisations, 2007-2010
Lupin: Financial Results, 2006-2010
Matrix: Manufacturing Facilities
Matrix: FDA ANDA Approvals, 2008-2010
Matrix: Tentative ANDA Approvals
Matrix: Financial Results, 2005-2009
Orchid: Manufacturing Facilities
Orchid: Key Subsidiaries and Joint Ventures
Orchid: Top Ten Brands
Orchid: FDA ANDA Approvals, 2005-2010
Orchid: UK MHRA Authorisations, 2008-2010
Orchid: Financial Results, 2006-2010
Piramal Healthcare: Manufacturing Facilities
Piramal Healthcare: Financial Results, 2006-2010
Piramal Healthcare: Formulations Sales by Therapeutic Area, 2007-2009 (Rs. Million)
Ranbaxy: Manufacturing Facilities
Ranbaxy: Regional Headquarters & Key Subsidiaries
Ranbaxy Laboratories: FDA ANDA Approvals, 2002-2009
Ohm Laboratories: FDA ANDA Approvals, 2006-2009
UK MHRA Marketing Authorisations, 2006-2010
Ranbaxy: ANVISA Registered Generics, 2009
Ranbaxy: Financial Results, 2005-2009
Ranbaxy: Sales by Region, 2009
Strides Arcolab: Manufacturing Facilities
Strides Arcolab: Key Subsidiaries
Akorn Strides: FDA ANDA Approvals, 2007-2009
Sagent Strides: FDA ANDA Approvals
Strides Arcolab FDA ANDA Approvals
Strides: Financial Results, 2005-2009
Sun Pharma: Manufacturing Facilities
Sun Pharma: Key Subsidiaries
Sun Pharma: FDA ANDA Approvals, 2006-2009
Caraco Pharmaceutical: ANDA Approvals, 2002-2008
Sun Pharma Tentative ANDA Approvals
Sun Pharma UK Marketing Authorisations, 2008-2010
Sun Pharma: Financial Results, 2006-2010
Torrent Pharma: Manufacturing Facilities
Torrent Pharma: Key Subsidiaries
Torrent Pharma: FDA ANDA Approvals, 2007-2010
Torrent Pharma: Financial Results, 2006-2010
International Sales by Region, 2009
Wockhardt Manufacturing Facilities
Wockhardt: Key Subsidiaries
Wockhardt: FDA ANDA Approvals, 2003-2009
Wockhardt UK Marketing Authorisations, 2006-2009
Pinewood Laboratories UK Marketing Authorisations, 2006-2009
Wockhardt: Financial Results, 2005-2009
Wockhardt Sales by Region, 2008
Zydus Cadila: Manufacturing Facilities
Zydus Cadila: Key Subsidiaries
Zydus: ANDA Approvals, 2005-2009
Zydus: Tentative FDA ANDA Approvals
Zydus ANVISA Registered Generics, 2009
Zydus Cadila: Financial Results, 2006-2010

LIST OF FIGURES

Map: Indian Pharmaceutical Company Headquarters
Map: Manufacturing Locations in India
Map: Indian Companies in the US
Map: Indian Companies in the UK and Ireland
Map: Indian Companies in Continental Europe
Map: Indian Companies in Brazil
Map: Indian Companies in China
Exports of Raw Materials & Retail Medicaments, 1998-2008 (US$000)
Pharmaceutical Exports by Category, 1998 & 2008 (%)
Pharmaceutical Export Growth, 1999-2008 (%)
Cipla: Exports by Region, 2009 (%)
Dr. Reddy’s: Generic Sales by Region, 2010 (%)
Glenmark: Formulations Sales by Region, 2010 (%)
Matrix: Sales by Region, 2009 (%)
Piramal Formulations Revenue by Therapeutic Area, 2009 (%)
Ranbaxy: Sales by Region, 2009 (%)
Strides: Revenue by Region, 2008
Torrent Pharma: International Sales by Region, 2009 (%)
Wockhardt: Sales by Region, 2008 (%)
Zydus Cadila: Formulation Sales by Region, 2009 (%)
Zydus Cadila: Domestic Formulations Sales by Therapy Area, 2009 (%)
Skip to top


Analyzing the Indian Pharmaceutical Industry US$ 300.00 Mar, 2012 · 75 pages
Analyzing the Indian Retail Industry US$ 450.00 Jun, 2011 · 400 pages
Analyzing the Indian Steel Industry 2016 US$ 850.00 Aug, 2016 · 260 pages

Ask Your Question

The Indian Pharmaceutical Industry: New Strategies in a Changing World
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: